NZ602685A - Concentrated protein formulations and uses thereof - Google Patents
Concentrated protein formulations and uses thereofInfo
- Publication number
- NZ602685A NZ602685A NZ602685A NZ60268511A NZ602685A NZ 602685 A NZ602685 A NZ 602685A NZ 602685 A NZ602685 A NZ 602685A NZ 60268511 A NZ60268511 A NZ 60268511A NZ 602685 A NZ602685 A NZ 602685A
- Authority
- NZ
- New Zealand
- Prior art keywords
- concentrated protein
- protein formulations
- formulation
- buffer
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33919110P | 2010-03-01 | 2010-03-01 | |
| PCT/US2011/026647 WO2011109365A2 (en) | 2010-03-01 | 2011-03-01 | Concentrated protein formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ602685A true NZ602685A (en) | 2014-10-31 |
Family
ID=44542798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ602685A NZ602685A (en) | 2010-03-01 | 2011-03-01 | Concentrated protein formulations and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9956165B2 (OSRAM) |
| EP (1) | EP2542221A4 (OSRAM) |
| JP (2) | JP5937523B2 (OSRAM) |
| KR (1) | KR101853981B1 (OSRAM) |
| CN (2) | CN102946861B (OSRAM) |
| AU (2) | AU2011223805B2 (OSRAM) |
| BR (1) | BR112012022223B1 (OSRAM) |
| CA (1) | CA2794929C (OSRAM) |
| IL (1) | IL221748B (OSRAM) |
| MX (1) | MX347504B (OSRAM) |
| NZ (1) | NZ602685A (OSRAM) |
| RU (1) | RU2626512C2 (OSRAM) |
| SG (1) | SG184355A1 (OSRAM) |
| WO (1) | WO2011109365A2 (OSRAM) |
| ZA (1) | ZA201207331B (OSRAM) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5937523B2 (ja) * | 2010-03-01 | 2016-06-22 | サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． | 濃縮されたタンパク質製剤およびその使用 |
| EP2635601B1 (en) | 2010-11-04 | 2016-07-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
| AU2012328524B2 (en) * | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| AU2013221635B2 (en) * | 2012-02-16 | 2017-12-07 | Santarus, Inc. | Anti-VLA1 (CD49a) antibody pharmaceutical compositions |
| WO2013165791A1 (en) | 2012-05-03 | 2013-11-07 | Boehringer Ingelheim International Gmbh | Anti-il-23p19 antibodies |
| PE20191815A1 (es) | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
| CN109999195A (zh) * | 2012-09-20 | 2019-07-12 | 莫弗系统股份公司 | 类风湿关节炎的治疗 |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3050557A1 (en) | 2014-05-23 | 2016-08-03 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| CN106661113A (zh) * | 2014-08-20 | 2017-05-10 | 西托戴恩股份有限公司 | Hiv抗体治疗作为治疗替代 |
| US10059763B2 (en) | 2014-09-03 | 2018-08-28 | Boehringer Ingelheim International Gmbh | Compound targeting IL-23A and TNF-alpha and uses thereof |
| MX391067B (es) | 2014-10-01 | 2025-03-21 | Eagle Biologics Inc | Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad. |
| EP3207061A1 (en) * | 2014-10-18 | 2017-08-23 | Pfizer Inc | Anti-il-7r antibody compositions |
| JP6781508B2 (ja) | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| BR112017014376A2 (en) | 2015-01-28 | 2018-05-02 | Pfizer Inc. | stable aqueous formulation of vascular endothelial growth antifactor (vegf) antibodies and use |
| IL307578A (en) | 2015-02-04 | 2023-12-01 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3256154B1 (en) * | 2015-02-09 | 2019-10-02 | UCB Biopharma SPRL | Pharmaceutical formulation comprising antibody |
| EP3081942A1 (en) * | 2015-04-17 | 2016-10-19 | Roche Diagniostics GmbH | Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| WO2016210130A1 (en) * | 2015-06-23 | 2016-12-29 | Cytodyn Inc. | Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| TW201726111A (zh) * | 2015-09-30 | 2017-08-01 | 持田製藥股份有限公司 | 含高濃度抗體之液體製劑 |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| EP4516319A3 (en) * | 2015-11-03 | 2025-05-07 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| JP7224917B2 (ja) | 2016-03-31 | 2023-02-20 | ソリッソ ファーマシューティカルズ，インク． | 組成物 |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| TWI826351B (zh) * | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧（杭州）生物醫藥有限公司 | Ｒ抗體,其藥物組合物及其應用 |
| AU2017305856B2 (en) | 2016-08-05 | 2024-09-12 | Csl Behring Gmbh | Pharmaceutical formulations of C1 esterase inhibitor |
| CN112057419B (zh) * | 2017-03-01 | 2023-08-22 | 免疫医疗有限公司 | 单克隆抗体的配制品 |
| CN110769848A (zh) * | 2017-05-16 | 2020-02-07 | 瑞士奥克特珐玛公司 | C1-酯酶抑制剂制剂 |
| JP2020530004A (ja) * | 2017-08-03 | 2020-10-15 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 核酸を高濃度で含む製剤 |
| KR102208378B1 (ko) * | 2017-08-17 | 2021-01-28 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| US20190085086A1 (en) | 2017-09-18 | 2019-03-21 | Cytodyn Inc. | Screening methods for identifying and treating hiv-1 infected patient sub-populations suitable for long term anti-ccr5 agent therapy |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| KR20210021299A (ko) | 2018-05-10 | 2021-02-25 | 리제너론 파아마슈티컬스, 인크. | 고농도 vegf 수용체 융합 단백질 함유 제제 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| EP3934617A1 (en) | 2019-03-08 | 2022-01-12 | Boehringer Ingelheim International GmbH | Anti-il-36r antibody formulations |
| MA55750A (fr) * | 2019-04-23 | 2022-03-02 | Sanofi Sa | Formulations d'anticorps stables et à faible viscosité et leurs utilisations |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| EP4139352A1 (en) * | 2020-04-22 | 2023-03-01 | Chemomab Ltd. | Method of treatment using anti-ccl24 antibody |
| CN111595658B (zh) * | 2020-06-06 | 2023-11-14 | 宾傲 | 一种提取细胞中蛋白的裂解液及其制备方法 |
| CN116034985B (zh) * | 2022-12-12 | 2025-09-16 | 武汉呵尔医疗科技发展有限公司 | 一种细胞保护液、hpv e6/e7质控片的制备方法及应用 |
| WO2025089468A1 (ko) * | 2023-10-27 | 2025-05-01 | 주식회사 엔솔바이오사이언스 | 펩타이드 함유 액상제제 및 그 제조방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1516628T1 (sl) | 1995-07-27 | 2013-10-30 | Genentech, Inc. | Stabilna izotonična liofilizirana proteinska formulacija |
| IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| CN1607958A (zh) * | 2001-12-21 | 2005-04-20 | 诺和诺德医疗保健公司 | 因子ⅶ多肽的液体组合物 |
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
| CN1780907B (zh) | 2002-02-22 | 2011-06-15 | 原基因药物有限公司 | 抗ccr5抗体 |
| DK1478394T3 (da) * | 2002-02-27 | 2008-10-13 | Immunex Corp | Stabiliseret TNFR-Fc formulation med arginin |
| JP4607010B2 (ja) | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | タンパク質含有安定化製剤 |
| DK2335725T3 (en) * | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
| CA2566075A1 (en) | 2004-05-12 | 2005-12-01 | Baxter Healthcare S.A. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
| CN1993139B (zh) * | 2004-06-01 | 2011-02-16 | 阿雷斯贸易股份有限公司 | 稳定的干扰素液体制剂 |
| WO2006007412A2 (en) * | 2004-06-16 | 2006-01-19 | Nastech Pharmaceutical Company Inc. | Peptide yy formulations having increased stability and resistance to microbial agents |
| AU2006291005A1 (en) | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-CD3 antibody formulations |
| EP3225233B1 (en) | 2005-11-01 | 2019-08-14 | Wyeth LLC | Sodium chloride solution for drug reconstitution |
| CN101378782A (zh) * | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| WO2008051363A2 (en) | 2006-10-20 | 2008-05-02 | Amgen Inc. | Stable polypeptide formulations |
| JP5937523B2 (ja) * | 2010-03-01 | 2016-06-22 | サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． | 濃縮されたタンパク質製剤およびその使用 |
-
2011
- 2011-03-01 JP JP2012556165A patent/JP5937523B2/ja active Active
- 2011-03-01 CN CN201180019594.5A patent/CN102946861B/zh active Active
- 2011-03-01 SG SG2012072542A patent/SG184355A1/en unknown
- 2011-03-01 RU RU2012141655A patent/RU2626512C2/ru active
- 2011-03-01 KR KR1020127025849A patent/KR101853981B1/ko active Active
- 2011-03-01 CN CN201510815109.5A patent/CN105521491B/zh active Active
- 2011-03-01 BR BR112012022223-6A patent/BR112012022223B1/pt active IP Right Grant
- 2011-03-01 WO PCT/US2011/026647 patent/WO2011109365A2/en not_active Ceased
- 2011-03-01 AU AU2011223805A patent/AU2011223805B2/en active Active
- 2011-03-01 US US13/582,243 patent/US9956165B2/en active Active
- 2011-03-01 MX MX2012010114A patent/MX347504B/es active IP Right Grant
- 2011-03-01 CA CA2794929A patent/CA2794929C/en active Active
- 2011-03-01 EP EP11751179.0A patent/EP2542221A4/en active Pending
- 2011-03-01 NZ NZ602685A patent/NZ602685A/en unknown
-
2012
- 2012-09-02 IL IL221748A patent/IL221748B/en active IP Right Grant
- 2012-10-01 ZA ZA2012/07331A patent/ZA201207331B/en unknown
-
2016
- 2016-01-28 AU AU2016200495A patent/AU2016200495B2/en active Active
- 2016-05-11 JP JP2016095589A patent/JP6229007B2/ja active Active
-
2018
- 2018-03-19 US US15/925,255 patent/US11571383B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ602685A (en) | Concentrated protein formulations and uses thereof | |
| NZ593190A (en) | Factor viii formulations | |
| MX2009002547A (es) | Composiciones terapeuticas de peptido de fusion. | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| IN2014CN02592A (OSRAM) | ||
| NZ610346A (en) | Hyaluronic acid based formulations | |
| PE20080658A1 (es) | Formulaciones de metilnaltrexona en forma de polvo seco | |
| MY156188A (en) | Long - acting formulations of insulins | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| MX2010006370A (es) | Composiciones de activo antitranspirante que tienen un cromatograma sec que exhibe una intensidad de pico 4 sec elevada. | |
| EA201492021A1 (ru) | Антительный состав | |
| MD20140134A2 (ro) | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice | |
| MX2011013722A (es) | Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños. | |
| UA104888C2 (uk) | Ад'ювантна композиція, що містить неіонний ізотонічний агент | |
| UA95105C2 (ru) | Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения | |
| EA201791111A1 (ru) | Пероральная регидратационанная композиция и способы | |
| MY184736A (en) | Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations | |
| PH12015502542A1 (en) | Stabilized pemetrexed formulation | |
| MY163100A (en) | Short antimicrobial lipopeptides | |
| RU2013156999A (ru) | Композиции для ухода за полостью рта, содержащие фитиновую кислоту | |
| FI3817751T3 (fi) | Vedettömän natriumtiosulfaatin formulaatioita | |
| ZA201504103B (en) | Organ and tissue preservation formulations with increased stability and shelf life | |
| WO2011163651A3 (en) | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE | |
| TN2013000386A1 (en) | Suspension type topical formulations comprising cyclic depsipeptide | |
| TN2014000152A1 (en) | Sustained-release preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: CYTODYN INC., US Effective date: 20130911 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2016 BY COMPUTER PACKAGES INC Effective date: 20150519 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2017 BY COMPUTER PACKAGES INC Effective date: 20160218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2018 BY COMPUTER PACKAGES INC Effective date: 20170218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2019 BY COMPUTER PACKAGES INC Effective date: 20180220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2020 BY COMPUTER PACKAGES INC Effective date: 20190219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2022 BY COMPUTER PACKAGES INC Effective date: 20210306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2023 BY COMPUTER PACKAGES INC Effective date: 20220217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2024 BY COMPUTER PACKAGES INC Effective date: 20230317 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2025 BY COMPUTER PACKAGES INC Effective date: 20240229 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2026 BY COMPUTER PACKAGES INC Effective date: 20250301 |